RxDoctor Payments Data

Jamil Dihu, DO

Cardiovascular Disease · Evanston, ILNPI 1154508570

Payments from drug & device makers

$83,352in general payments, 2019–2025

Across 278 payments — averaging $299.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$67K
  • Abbott$8K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6K
  • Novartis$377
  • Abiomed$319
  • Penumbra, Inc.$286
  • plus $1K from 19 others

What the payments were for

  • Consulting fees$6,5638%
  • Speaking & faculty fees$65,25078%
  • Travel & lodging$3,4344%
  • Food & beverage$7,95710%
  • Education$1480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,352 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$41,664
Medicare patients
375
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan17$22,373
XareltoRivaroxaban13$18,024
Metoprolol Succinate60$848
Spironolactone82$736
Atorvastatin Calcium71$584
Nifedipine ErNifedipine11$451
Furosemide56$414
Enalapril Maleate17$332
Lisinopril32$241
Isosorbide Mononitrate ErIsosorbide Mononitrate18$221
Carvedilol27$220
Hydralazine Hcl16$177
Amlodipine Besylate18$98
Losartan Potassium19$65
Hydrochlorothiazide12$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$377$22,37317 claims
Johnson & JohnsonXarelto$200$18,02413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →